Skip to content
ppharmaranks
Menu
Class IIOngoing

Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx,… recall

FDA recall D-0650-2024 · initiated Aug 22, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Sep 11, 2024How we research

ProRx LLC recalled Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass via… in Aug 2024 — an FDA Class II recall (D-0650-2024) because Lack of Assurance of Sterility.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Lack of Assurance of Sterility

Sterility could not be assured

The maker could not guarantee the product was sterile. That matters most for injections and eye products, where a contaminated dose reaches past the body's defences.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: ProRx031924, BUD 09/18/2024 ProRx032624, BUD 09/25/2024 ProRx041324, BUD 10/12/2024

Quantity recalled: 2,490 vials

Details

Product
Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01
Recalling company
ProRx LLC
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Aug 22, 2024
FDA report date
Sep 11, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass via… recalled?
ProRx LLC recalled Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass via… in Aug 2024 — an FDA Class II recall (D-0650-2024) because Lack of Assurance of Sterility. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass via… recalled?
Per the FDA enforcement record, the reason for recall D-0650-2024 was: Lack of Assurance of Sterility
Is a recalled Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass via… dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass via… are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot #: ProRx031924, BUD 09/18/2024 ProRx032624, BUD 09/25/2024 ProRx041324, BUD 10/12/2024. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0650-2024.

Source: openFDA Drug Enforcement record D-0650-2024

← All drug recalls